

Home > TopNews

Accelerate Your Research  
Centrifuge 5910 Ri  
[Learn more](#)

you can get e-magazine links on WhatsApp. [Click here](#)

### Patents

+ Font  
- Resize

## Dr Sanjay Agrawal files patent application for new Thalassemia formulation

Shardul Nautiyal, Mumbai  
Tuesday, August 20, 2024, 08:00 Hrs [IST]

Addressing the critical need for innovative and effective treatment in Thalassemia, Dr Sanjay Agrawal, a distinguished pharmaceutical consultant and inventor, with two decades of experience in research, has filed a patent at the Indian Patent Office, Delhi for the development of a new formulation. This unique formulation represents a significant leap forward in the treatment of Thalassemia, promising to improve patient outcomes and offer a better quality of life.

The implications of Dr. Agrawal's formulation extend far beyond Thalassemia. This breakthrough could pave the way for new treatments for other genetic blood disorders, offering hope to millions of patients worldwide. As research continues, there is potential for the development of even more advanced therapies that could one day lead to a cure for Thalassemia and related conditions.

Thalassemia, a hereditary blood disorder affecting millions globally, presents a formidable challenge in modern medicine. The disease, which hinders the body's ability to produce sufficient hemoglobin, results in severe anaemia and requires lifelong blood transfusions and intensive medical care. The physical, emotional, and financial burdens placed on patients and their families are immense, underscoring the need for innovative and effective treatments.

Thalassemia is a genetic disorder primarily affecting the production of hemoglobin, the protein in red blood cells responsible for carrying oxygen throughout the body. Patients with Thalassemia suffer from chronic fatigue, developmental delays, and other severe health issues due to the constant lack of sufficient oxygen in their tissues. Regular blood transfusions, though life-saving, come with their own risks, including iron overload, which can lead to further complications such as heart disease, liver damage, and diabetes.

"While advancements in medical technology have improved the management of Thalassemia, the need for a more effective, safer, and long-term solution remains urgent. Current treatments often involve a combination of blood transfusions and chelation therapy to remove excess iron, but these can be both physically taxing and financially burdensome for patients. "This is where the new formulation comes into play" explains Dr Sanjay Agrawal.

VEEGUM  
Suspension & Emulsion Stabilization

[f Share](#) [X Tweet](#) [Share](#) [in Share](#)

[Printer-Friendly Version](#) [Email This Article](#)

[<< BACK](#)

**POST YOUR COMMENT**

Comments

\* Name :

\* Email :

Website :

SUBSCRIBE NOW!  
CHRONICLE  
PHARMABIZ

AVIANS  
Advancing ideas and leading the industry

VACCINE  
Leaders Conclave

CPHI Korea  
27-29 AUG 2024 | Seoul Korea

High Speed Doors  
for Clean Room  
Application

Pharmabiz e-paper

LOW TEMPERATURE  
AQUEOUS  
COATING.

STAND OUT!

GOOD CLINICAL PRACTICES

Ingredients  
SOUTH ASIA

9.8k Shares

[X](#)

[f](#)

[in](#)